Key result
An OFDI-guided management strategy limiting durable intracoronary devices in young STEMI patients resulted in only 1 major adverse cardiac event (2.2%) at six months.
Why the study?
Does an OFDI-guided strategy limiting durable intracoronary devices provide safe and feasible management in young patients with STEMI and single-vessel disease?
Cohort (n=45)
Does an OFDI-guided strategy limiting durable intracoronary devices provide safe and feasible management in young patients with STEMI and single-vessel disease?
An OFDI-guided strategy to limit durable stent implantation in young STEMI patients by using bioresorbable scaffolds or medical therapy alone appears feasible and safe at 6 months.
AIMS: The aim of this study was to demonstrate the feasibility and safety of ST-elevation myocardial infarction (STEMI) management in young patients by limiting implantation of durable intracoronary devices (using a bioresorbable stent or medical treatment alone). METHODS AND RESULTS: Patients <50 years old admitted for STEMI with single-vessel disease received a two-stage management strategy. During a second coronary angiography performed between day 2 and day 7, optical frequency domain imaging (OFDI) guided the decision on therapeutic management, i.e., i) in the case of a stenosis greater than 70% or plaque prolapse, implantation of a BVS; or ii) in the other cases, continuation of medical management alone without stenting. All patients underwent systematic angiographic control with OFDI imaging at six months. Among the 653 patients admitted for STEMI, 124 patients were under 50 years old and 45 patients were included. Early management was performed on average at day 3.9 (day 2 - day 7). Thirty-four (34) patients received BVS implantation and 11 were treated medically. Only one major adverse cardiac event (MACE) had occurred at six months. CONCLUSIONS: In a selected younger population, the management of STEMI guided by OFDI and based on the concept of limiting implantation of durable intracoronary devices appears to be a feasible and safe therapeutic option.
No takes yet. Share an insight, caveat, or question.
Combaret et al. (2017) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=45). OFDI-guided management limiting durable intracoronary devices was evaluated on Major adverse cardiac event (MACE) at six months. An OFDI-guided management strategy limiting durable intracoronary devices in young STEMI patients resulted in only 1 major adverse cardiac event (2.2%) at six months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: